President-elect of Sumitomo Pharma disclosed key regenerative medicine

Sumitomo Pharma is in a difficult situation due to the expiry of patents on its main pharmaceutical products and sluggish sales growth of the products it has introduced. President-elect Kimura, who will take over as president on 25th of this month, talks about regenerative medicine for Parkinson's disease, for which clinical trials have started in the US, which is key to the company's turnaround offensive.
https://miyata-bio.net/column/0000350/